`
`Inventors: GARCIA COLLAZO et al.
`
`Confirmation No.: 6385
`
`Applicant: Minoryx Therapeutics S.L.
`
`Application No.: 16/474,461
`
`(US. nationalphase ofInternational
`
`Application No. PCT/IB201 7/0584 77
`
`International Filing Date: December 28,
`
`201 7)
`
`
`
`Art Unit: 1629
`
`Examiner: To Be Assigned
`
`Atty. Docket: 43 15 .002000 1/TJS/THN
`
`Title: HETEROARYL COMPOUNDS AND THEIR USE
`
`Information Disclosure Statement
`
`Mail Stop Amendment
`
`Commissioner for Patents
`
`PO Box 1450
`
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`Listed on accompanying forms equivalent to forms PTO/SB/08a and PTO/SB/08b are
`
`documents that may be considered material to the patentability of this application as defined in 37
`
`CPR. §1.56. These documents are being provided to the Office in compliance with the duty of
`
`disclosure requirements of 37 CPR. §§ 1.97 and 1.98.
`
`Applicant has listed publication dates on the attached IDS Forms based on information
`
`presently available to the undersigned. However, the listed publication dates should not be
`
`construed as an admission that the information was actually published on the date indicated.
`
`Applicant reserves the right to establish the patentability of the claimed invention over any
`
`of the information provided herewith, and/or to prove that this information may not be prior art,
`
`and/or to prove that this information may not be enabling for the teachings purportedly offered.
`
`
`
`— 2 —
`
`GARCIA COLLAZO el 61].
`
`Application No. 16/474,461
`
`This statement should not be construed as a representation that a search has been made, or
`
`that information more material to the examination of the present patent application does not exist.
`
`The Examiner is specifically requested not to rely solely on the material submitted herewith.
`
`This is a filing under 37 C.F.R. § l.97(b). This Information Disclosure Statement is being
`
`filed before the mailing date of a first Office Action on the merits. No statement or fee is required.
`
`A concise explanation of the relevance of the non-English language documents appears
`
`below in accordance with 37 C.F.R. § l.98(a)(3).
`
`Document FPl, WO-2004039796-A1, is in a foreign language. An English language
`
`abstract is appended to the face page of document FPl. Additionally, document US1, US-7737 153-
`
`B2, is believed to be an English language equivalent of document FPl.
`
`Document FPZ, WO-2004039797-A1, is in a foreign language. An English language
`
`abstract is appended to the face page of document FP2.
`
`Copies of documents FPl-FP17 and NPLl-NPL32 are submitted. However, in accordance
`
`with 37 C.F.R. § l.98(a)(2)(ii), no copies of US. patent and patent application publication cited as
`
`documents US1 and US2 on the attached IDS Form are submitted.
`
`It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS
`
`Forms, and indicate in the official file wrapper of this patent application that the documents have
`
`been considered.
`
`Atty. Dkt. No. 4315.0020001/TJS/THN
`
`
`
`— 3 —
`
`GARClA COLLAZO el 61].
`
`Application No. 16/474,461
`
`The US. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or
`
`credit any overpayment, to our Deposit Account No. 19-0036.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`
`Timothy J. Shea, Jr.
`Attorney for Applicant
`Registration No. 41,306
`
`Date: November 1, 2019
`
`1100 New York Avenue, NW.
`Washington, DC. 20005-3934
`(202) 371-2600
`
`1407073 l_l.d0CX
`
`Atty. Dkt. No. 4315.0020001/TJS/THN
`
`